July 14, 2025 – Barcelona, Spain
Barcelona Liver Bioservices (BLB) is proud to announce the publication of a groundbreaking study in collaboration withGAT Therapeutics, presenting compelling preclinical evidence for the efficacy of GTX-11 in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)—a rapidly growing global health challenge with no currently approved therapies.
The study evaluated GTX-11, a first-in-class compound with anti-inflammatory and anti-fibrotic activity via TGFβ pathway modulation, using BLB’s advanced in vivo and ex vivo liver disease models. Leveraging BLB’s translational platforms, including a robust MASH rat model and human precision-cut liver slices (hPCLS), the research revealed the drug’s potential to reverse key pathological features of the disease.
Key findings:
- Significant dose-dependent reduction in portal pressure and hepatic fibrosis in MASH rats treated with GTX-11
- Deactivation of hepatic stellate cells and re-differentiation of liver endothelial cells, highlighting the drug’s mechanism of action
- Transcriptomic analysis of hPCLS confirmed anti-fibrotic effects and extracellular matrix remodeling in human liver tissue
- Gene deconvolution analysis demonstrated a consistent rebalancing of the fibrotic microenvironment
“This study underscores BLB’s ability to bridge preclinical and translational research using disease-relevant models,” said Dr. Jordi Gracia-Sancho, Scientific Director at BLB. “Our integrated approach helped validate GTX-11 not only in vivo, but also in human tissue—an essential step toward clinical application.”
GTX-11 now emerges as a strong candidate for clinical development, offering new hope for patients suffering from MASH, a condition that affects over 3–6% of the global population and continues to rise in prevalence.
Read the full paper here: https://www.jhep-reports.eu/article/S2589-5559(25)00175-2/fulltext
BLB remains committed to accelerating the development of new treatments for liver diseases by partnering with biotech and pharma companies worldwide.
About Barcelona Liver Bioservices (BLB)
Barcelona Liver Bioservices is a specialized CRO focused on translational research in liver diseases. With cutting-edge in vivo, ex vivo, and omics-based platforms, BLB provides customized preclinical solutions to support drug discovery and development in hepatology.
🔗 To learn more about our services or explore potential collaborations, visit: https://liver.barcelona/